Get the Stockscreener App
19.95
1.59%
0.365
Avalo Therapeutics Inc stock is traded at $19.95, with a volume of 397.23K.
It is up +1.59% in the last 24 hours and up +2.74% over the past month.
Avalo Therapeutics Inc is a clinical stage biotechnology company fully dedicated to developing IL-1B-based treatments for immune-mediated inflammatory diseases. The company's asset is Abdakibart (AVTX-009) an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.
See More
Previous Close:
$19.59
Open:
$19.48
24h Volume:
397.23K
Relative Volume:
0.29
Market Cap:
$1.07B
Revenue:
$59,000
Net Income/Loss:
$-84.74M
P/E Ratio:
-3.4274
EPS:
-5.8222
Net Cash Flow:
$-59.69M
1W Performance:
+0.67%
1M Performance:
+2.74%
6M Performance:
+32.06%
1Y Performance:
+120.64%
1-Day Range:
$19.32
$20.07
1-Week Range:
$18.34
$20.07
52-Week Range:
$8.41
$24.27
Avalo Therapeutics Inc Stock (AVTX) Company Profile
Name
Avalo Therapeutics Inc
Sector
Industry
Phone
410-522-8707
Address
1500 LIBERTY RIDGE DRIVE, WAYNE
Compare AVTX vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AVTX
Avalo Therapeutics Inc
|
19.96 | 1.05B | 59,000 | -84.74M | -59.69M | -5.8222 |
VRTX
Vertex Pharmaceuticals Inc
|
515.44 | 128.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
806.90 | 82.72B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
992.82 | 53.26B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
215.68 | 43.66B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
362.27 | 39.31B | 5.76B | 514.49M | 1.10B | 4.4813 |
Avalo Therapeutics Inc Stock (AVTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-09-26 | Initiated | Wolfe Research | Outperform |
| Apr-06-26 | Initiated | Citizens | Mkt Outperform |
| Feb-02-26 | Initiated | Guggenheim | Buy |
| Dec-18-25 | Initiated | Mizuho | Outperform |
| Sep-17-25 | Reiterated | H.C. Wainwright | Buy |
| Sep-05-25 | Initiated | TD Cowen | Buy |
| Aug-15-25 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-02-25 | Resumed | H.C. Wainwright | Buy |
| Mar-25-25 | Initiated | Jefferies | Buy |
| Mar-25-25 | Initiated | Stifel | Buy |
| Feb-28-25 | Initiated | Piper Sandler | Overweight |
| Feb-21-25 | Initiated | Wedbush | Outperform |
| Dec-19-24 | Initiated | BTIG Research | Buy |
| Oct-24-24 | Initiated | H.C. Wainwright | Neutral |
| Apr-16-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Sep-24-21 | Initiated | RBC Capital Mkts | Outperform |
View All
Avalo Therapeutics Inc Stock (AVTX) Latest News
Wall Street Zen Upgrades Avalo Therapeutics (NASDAQ:AVTX) to Hold - marketbeat.com
Why Did AVTX Stock Surge 45% In Pre-Market Today? - Stocktwits
Avalo Therapeutics CSO Jennifer Riley sells $52,012 in stock By Investing.com - Investing.com Nigeria
Avalo Therapeutics CSO Jennifer Riley sells $52,012 in stock - Investing.com
Avalo Therapeutics CMO Mittie Doyle sells $13,580 in stock - Investing.com
AVTX Surges Over 50% After Hours as Skin Disease Drug Shows Desired Clinical Results - Stocktwits
Avalo Therapeutics Stock Price Forecast. Should You Buy AVTX? - StockInvest.us
Caligan Partners (NASDAQ: AVTX) reports 5.9% Avalo Therapeutics ownership on amended 13G - Stock Titan
RA Capital discloses 3.48M-share Avalo Therapeutics (AVTX) position in latest filing - Stock Titan
Avoro Capital and Behzad Aghazadeh report 4.44% AVTX stake in 13G/A filing - Stock Titan
Sei Investments Co. Invests $849,000 in Avalo Therapeutics, Inc. $AVTX - marketbeat.com
Avalo Therapeutics (AVTX) sees 5.5% stake reported by Affinity Asset Advisors and Michael Cho - Stock Titan
Avalo Therapeutics (AVTX) Chief Strategy Officer Jennifer Riley Sells 2,655 Shares - GuruFocus
Avalo Therapeutics (AVTX) CMO Mittie Doyle exercises options and sells 679 shares - Stock Titan
Avalo Therapeutics (AVTX) CSO Riley sells 2,655 shares at about $19.59 - Stock Titan
Avalo Therapeutics, Inc. $AVTX Shares Bought by Renaissance Technologies LLC - marketbeat.com
Avalo Therapeutics (AVTX) insider plans NASDAQ resale of 2,655 ESPP shares - Stock Titan
Equities Analysts Issue Forecasts for AVTX Q3 Earnings - marketbeat.com
Do Avalo Therapeutics’ (AVTX) Widening Losses But Better EPS Reveal a Turning Point in Strategy? - Yahoo Finance
Avalo Therapeutics (AVTX) Short Interest & Short Float | Updated Aug 2026 - marketbeat.com
Avalo Therapeutics (AVTX) insider schedules 679-share stock sale after option exercise - Stock Titan
Avalo Therapeutics (AVTX) Holds Near $18.29 as Shares Consolidate in a Narrow Trading BandSentiment Extreme - dars.gov.et
Avalo Therapeutics Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
Bank of America Securities Reaffirms Their Buy Rating on Avalo Therapeutics (AVTX) - The Globe and Mail
Avalo Therapeutics (NASDAQ:AVTX) Rating Lowered to "Sell" at Wall Street Zen - MarketBeat
A Quick Look at Today's Ratings for Avalo Therapeutics(AVTX.US), With a Forecast Between $30 to $58 - Moomoo
AVTX Maintains Buy Rating by Guggenheim -- Price Target Lowered to $48 - GuruFocus
Avalo Therapeutics Inc (AVTX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
FMR LLC discloses 10.8% Avalo Therapeutics (AVTX) holding in Schedule 13G/A - Stock Titan
AVTX Maintained by HC Wainwright & Co. -- Price Target Lowered t - GuruFocus
HC Wainwright Has Lowered Expectations for Avalo Therapeutics (NASDAQ:AVTX) Stock Price - MarketBeat
Avalo Therapeutics, Inc. (NASDAQ:AVTX) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
AVTX SWOT Analysis: Financial Challenges and Promising Pipeline Revealed in 10-Q Filing - GuruFocus
Avalo Therapeutics (NASDAQ:AVTX) Issues Quarterly Earnings Results, Misses Expectations By $0.27 EPS - MarketBeat
Price-Driven Insight from (AVTX) for Rule-Based Strategy - Stock Traders Daily
Avalo Therapeutics Releases Q2 2026 Financial Results - AlphaStreet
Avalo Therapeutics, Inc. Stock 12‑Month Price Target Raised to $45.33, Implies 141% Upside - TradingView
Avalo Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Avalo Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Updates - The Manila Times
Avalo Therapeutics Announces Plans for Phase 3 Abdakibart HS Program, Advancement of AVTX-010 and Second Quarter 2026 Financial Results - Quiver Quantitative
Avalo Therapeutics, Inc. 2026: Revenue ($36.94M), Net income ($36.36M), EPS ($0.83) — 10-Q Summary - TradingView
Avalo Therapeutics reports Q2 2026 net loss $36.4M; cash and investments $472.2M - TradingView
Avalo Therapeutics posts corporate deck spotlighting IL-1β inhibitor pipeline for hidradenitis suppurativa - Bitget
Avalo Therapeutics Inc expected to post a loss of 58 cents a shareEarnings Preview - TradingView
DV Trading LLC Invests $5.38 Million in Avalo Therapeutics, Inc. $AVTX - marketbeat.com
Avalo Therapeutics Inc Revenue Breakdown – DUS:C6K0 - TradingView
Avalo Therapeutics Inc (AVTX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Avalo Therapeutics (AVTX) Expected to Post Earnings on Thursday - marketbeat.com
Avalo Therapeutics earnings up next: Pipeline progress in focus By Investing.com - Investing.com Canada
Avalo Therapeutics (NASDAQ:AVTX) Insider Mittie Doyle Sells 1,000 Shares - marketbeat.com
Avalo Therapeutics Inc (AVTX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Avalo Therapeutics Inc Stock (AVTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Avalo Therapeutics Inc Stock (AVTX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Doyle Mittie | Chief Medical Officer |
Aug 10 '26 |
Option Exercise |
8.04 |
679 |
5,459 |
52,455 |
| Doyle Mittie | Chief Medical Officer |
Aug 10 '26 |
Sale |
20.00 |
679 |
13,580 |
51,776 |
2.24%
1.78%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):